Table 2.

OS (mo) in (A) Swedish and (B) Danish Patients Diagnosed With NSCLC by Age

	Incident Stage I–IIIA NSCLC						Incident Stage IIIB–IV NSCLC
	NSQ			SQ			NSQ			SQ
Age, y	N	Median OS (Q1–Q3), mo	1-y OS Probability (95% CI)	N	Median OS (Q1–Q3), mo	1-y OS Probability (95% CI)	N	Median OS (Q1–Q3), mo	1-y OS Probability (95% CI)	N	Median OS (Q1–Q3), mo	1-y OS Probability (95% CI)
<65	1632	83.5 (25.8–NE)	0.89 (0.88–0.91)	621	42.8 (16.0–NE)	0.81 (0.78–0.85)	3799	8.3 (3.5–18.1)	0.37 (0.35–0.38)	931	7.9 (3.6–16.8)	0.36 (0.33–0.39)
65–74	2269	57.0 (20.5–NE)	0.85 (0.84–0.87)	1143	34.7 (11.5–105.4)	0.74 (0.71–0.76)	4377	6.9 (2.7–15.4)	0.32 (0.31–0.34)	1464	6.2 (2.5–13.5)	0.28 (0.26–0.30)
≥75	1485	31.1 (12.1–76.9)	0.75 (0.73–0.77)	1058	16.4 (7.0– 46.3)	0.59 (0.56–0.62)	3285	4.9 (2.0–11.9)	0.25 (0.23–0.26)	1357	5.0 (2.2–10.4)	0.21 (0.19–0.23)

	Incident Stage I–IIIA NSCLC						Incident Stage IIIB–IV NSCLC
	NSQ			SQ			NSQ			SQ
Age, y	N	Median OS (Q1–Q3), mo	1-y OS Probability (95% CI)	N	Median OS (Q1–Q3), mo	1-y OS Probability (95% CI)	N	Median OS (Q1–Q3), mo	1-y OS Probability (95% CI)	N	Median OS (Q1–Q3), mo	1-y OS Probability (95% CI)
<65	1982	76.3 (23.6–NE)	0.88 (0.86–0.89)	796	37.7 (13.7–NE)	0.77 (0.74–0.80)	4462	7.4 (3.0–16.3)	0.33 (0.32–0.35)	1135	8.1 (3.4–16.0)	0.33 (0.31–0.36)
65–74	2028	55.0 (18.6–118.7)	0.83 (0.82–0.85)	1464	32.6 (11.4–99.6)	0.74 (0.71–0.76)	4035	5.9 (2.3–13.6)	0.28 (0.26–0.29)	1726	6.8 (2.9–14.0)	0.29 (0.27–0.32)
≥75	1270	27.7 (10.9–76.9)	0.72 (0.70–0.75)	1288	17.1 (6.9–49.1)	0.59 (0.57–0.62)	2758	4.2 (1.7–10.4)	0.21 (0.20–0.23)	1578	5.0 (2.1–10.5)	0.21 (0.19–0.23)

CI, confidence interval; NE, not estimable; NSQ, nonsquamous; OS, overall survival; Q, quartile; SQ, squamous.